Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib

BACKGROUND: Sorafenib, a multi-target kinase inhibitor, inhibits members of the MAPK pathway and receptor tyrosine kinases, including VEGF-R2. Sorafenib, carboplatin and paclitaxel (SCP) has anti-tumor activity in melanoma patients, but no association was found between response and activating B-Raf(...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Jilaveanu, Lucia, Zito, Christopher, Lee, Sandra J., Nathanson, Katherine L., Camp, Robert L., Rimm, David L., Flaherty, Keith T., Kluger, Harriet M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4263281/
https://ncbi.nlm.nih.gov/pubmed/19188183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2280
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller